Rigel Pharmaceuticals
41
10
11
22
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 40/100
9.8%
4 terminated/withdrawn out of 41 trials
84.6%
-1.9% vs industry average
17%
7 trials in Phase 3/4
73%
16 of 22 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (41)
An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis
Role: collaborator
Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy
Role: collaborator
Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations
Role: collaborator
A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm
Role: collaborator
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
Role: lead
Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax
Role: collaborator
A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
Role: collaborator
Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation
Role: collaborator
Fostamatinib for Treating Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Adults
Role: collaborator
Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD
Role: collaborator
Inflammatory Signal Inhibitors for COVID-19 (MATIS)
Role: collaborator
Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
Role: lead
Study of Olutasidenib and Temozolomide in HGG
Role: lead
Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer
Role: collaborator
Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer
Role: collaborator
Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy
Role: lead
Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia
Role: collaborator
Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
Role: lead
Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects
Role: lead
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA
Role: lead